Dianthus Therapeutics, Inc. (DNTH) vs Gilead Sciences, Inc. (GILD)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| DNTH | GILD | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | MID | LARGE |
| Listing | Nasdaq CM | Nasdaq GS |
| Country | United States | United States |
| Theme | rare-disease | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $79.33 | $158.69 |
| Return · 1 week | +6.43% | +3.67% |
| Return · 1 month | −9.68% | +4.26% |
| Return · 3 months | −21.93% | +18.14% |
| Return · year to date | +99.92% | +31.24% |
| Return · 1 year | +136.66% | +33.35% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −32.70% | −1.13% |
| 52-week high | $117.88 | $160.51 |
| 52-week low | $32.22 | $114.02 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $4.34B | $196.77B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $58.24M | $847.37M |
| Employees | 92 | 17,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | 15.64× |
| Price to sales | 2364.95× | 6.35× |
| Price to book | 3.85× | 16.37× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 14.71× |
| Enterprise value to revenue | 2028.46× | 7.05× |
| PEG ratio | — | 2.31 |
| Earnings per share · trailing | -4.23 | -2.65 |
| Profitability | ||
| Gross margin | — | 79.59% |
| Operating margin | −8079.11% | 33.68% |
| Profit margin | — | −10.64% |
| Return on equity | −26.07% | −20.68% |
| Return on assets | −17.69% | 14.09% |
| Growth | ||
| Revenue growth | +294.30% | +10.20% |
| Balance sheet and payout | ||
| Debt / equity (%) | 0.11 | 223.47 |
| Current ratio | 26.10 | 1.27 |
| Dividend yield | 0.00% | 2.10% |
| Payout ratio | 0.00% | 43.46% |
| Trend and volatility | ||
| RSI · 14 | 39.36 | 61.88 |
| ADX · 14 | 47.97 | 22.95 |
| 50-day average | $95.30 | $149.25 |
| 200-day average | $84.24 | $139.06 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 4.95% | 2.60% |
The full DNTH analysis
Everything this table leaves out for Dianthus Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the DNTH argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full DNTH analysisThe full GILD analysis
Everything this table leaves out for Gilead Sciences, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GILD argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GILD analysis